Yucai Wang, MD, PhD, Mayo Clinic, Rochester, MN, discusses a Phase II trial of pembrolizumab monotherapy and in combination with BCR inhibitors for Richter’s transformation (RT) of chronic lymphocytic leukemia (CLL). In the trial, 6 out of 26 patients responded to pembrolizumab monotherapy, while 10 out of 16 patients responded to the combination of pembrolizumab and BCR inhibitors. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.